Pretherapy nuclear factor-κB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma

Molecular Cancer Therapeutics

Volumn 5, Issue 11, 2006, Pages 2844-2850

  Izzo, Julie G ^a   Correa, Arlene M ^a   Wu, Tsung Teh ^a   Malhotra, Usha ^a   Chao, Clifford K S ^a   Luthra, Rajyalakshmi ^a   Ensor, Joe ^a   Dekovich, Alexander ^a   Liao, Zhongxing ^a   Hittelman, Walter N ^a   Aggarwal, Bharat B ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BIOLOGY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RESEARCH; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CARCINOMA; ESOPHAGUS SURGERY; FEMALE; FOLLOW UP; GENE CONTROL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS POTENTIAL; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INDUCTION; PROTEIN METABOLISM; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; THERAPY RESISTANCE; TREATMENT RESPONSE;

ADULT; AGED; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NF-KAPPA B; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33845217696     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0351     Document Type: Article

References (28)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349: 2241-52.
3. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-84.
4. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-7.
5. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-7.
6. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-13.
7. Vogel SB, Mendenhall WM, Sombeck MD, Marsh R, Woodward ER. Downstaging of esophageal cancer after preoperative radiation and chemotherapy. Ann Surg 1995;221:685-93.
8. Naunheim KS, Petruska PJ, Roy TS, Schlueter JM, Kim H, Baue AE. Multimodality therapy for adenocarcinoma of the esophagus. Ann Thorac Surg 1995;59:1085-90.
9. Bates BA, Detterbeck FC, Bernard SA, Qaqish BF, Tepper JE. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol 1996;14:156-63.
10. Heath EI, Burtness BA, Heitmiller RF, et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 2000; 18:868-76.
11. Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005;23:4330-7.
12. Rohatgi P, Swisher SG, Correa AM, et al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 2005;104:2365-72.
13. Jin J, Liao Z, Zhang Z, et al. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 2004;60:427-36.
14. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005;103:1347-55.
15. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006;441:431-6.
16. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev 2004;18: 2195-224.
17. Bottero V, Busuttil V, Loubat A, et al. Activation of nuclear factor κB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res 2001;61:7785-91.
18. Wang CY, Cusack JC, Jr., Liu R, Baldwin AS, Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999;5:412-7.
19. Wang CY, Guttridge DC, Mayo MW, Baldwin AS, Jr. NF-κB induces expression of the Bcl-2 homologue A1/BfI-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999;19:5923-9.
20. Cusack JC, Jr., Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res 2001;61:3535-40.
21. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ. Inhibition of AKT abrogates chemotherapy-induced NF-κB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg 2004;198: 591-9.
22. Sanchez-Perez I, Benitah SA, Martinez-Gomariz M, Lacal JC, Perona R. Cell stress and MEKK1-mediated c-Jun activation modulate NFκB activity and cell viability. Mol Biol Cell 2002;13:2933-45.
23. Aggarwal BB, Shishodia S, Takada Y, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-κB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005;11:7490-8.
24. Magne N, Toillon RA, Bottero V, et al. NF-κB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Lett 2006;231:158-68.
25. Luthra R, Wu TT, Luthra MG, et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 2006;24:259-67.
26. Izzo JG, Malhotra U, Wu TT, et al. Association of activated transcription factor nuclear factor κb with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 2006; 24:748-54.
27. Ajani JA, Faust J, Yao J, et al. Irinotecan/cisplatin followed by 5-FU/ paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Williston Park) 2003;17:20-2.
28. Ajani JA, Walsh G, Komaki R, et al. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 2004;100:2347-54.